2014
DOI: 10.1186/1465-9921-15-82
|View full text |Cite
|
Sign up to set email alerts
|

Moxifloxacin modulates inflammation during murine pneumonia

Abstract: BackgroundMoxifloxacin is a synthetic antibacterial agent belonging to the fluoroquinolone family. The antimicrobial activity of quinolones against Gram-positive and Gram-negative bacteria is based on their ability to inhibit topoisomerases. Quinolones are described to have immunomodulatory features in addition to their antimicrobial activities. It was the goal of this study to examine whether a short term treatment with moxifloxacin modulates the inflammation during a subsequently induced bacterial infection … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
20
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 20 publications
(20 citation statements)
references
References 29 publications
(43 reference statements)
0
20
0
Order By: Relevance
“…The inflammatory score was calculated as described previously (6). Primary antibodies for TNF-␣ (Abcam, UK) were used for immunohistochemistry analysis by a blinded investigator as described previously (32). Seven to 10 fields per lung were evaluated for TNF-␣-positive cells.…”
Section: Methodsmentioning
confidence: 99%
“…The inflammatory score was calculated as described previously (6). Primary antibodies for TNF-␣ (Abcam, UK) were used for immunohistochemistry analysis by a blinded investigator as described previously (32). Seven to 10 fields per lung were evaluated for TNF-␣-positive cells.…”
Section: Methodsmentioning
confidence: 99%
“…10,17 The expression of IL-17A was found to be increased in mouse lungs infected with P. aeruginosa. 11,[18][19][20][21] Il-17A-dependent acquired immunity is also required for efficient clearance of Streptococcus pneumoniae in the upper airways. 13,16 Recent studies suggest that IL-17A plays a major role in the pathogenesis of acute respiratory distress syndrome (ARDS).…”
Section: Introductionmentioning
confidence: 99%
“…It inhibits the synthesis of inflammatory mediators and the activation of MAP kinase and NF-kB signaling cascades [11]. In the study of Beisswenger et al [12]showed that moxifloxacin treatment resulted in low levels of pro-inflammatory mediators and neutrophils in the lungs of mice infected with Streptococcus pneumoniae and Pseudomonas aeruginosa. The immunomodulatory effects of moxifloxacin may result in the changes of WBC count like leukopenia with neutropenia at clinically relevant concentrations.…”
Section: Discussionmentioning
confidence: 99%